PTCT at a glance
PTC THERAPEUTICS, INC. (PTCT, SEC CIK 1070081) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding PTC THERAPEUTICS, INC. (PTCT) shares worth $2.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Boulding Mark Elliott on November 16, 2026 of 209 shares at $62.90 per share.
- In the last 90 days, PTCT insiders reported 0 open-market purchases ($0) and 22 open-market sales ($5.9M) on Form 4, a net sale of $5.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.7B
- +114.5% vs prior year
- Insiders · 90 days
- 0 buys · 22 sells
- Net −$5.9M
- 13F holders
- 34 funds
- $2.6B · +0 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 7.01 · Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of treatments for rare diseases, with focus on sepiapterin programs from Censa acquisition
- Strategic shift: Rights Satisfaction Agreement canceled contingent net sales payments, replaced with upfront $225.1M cash payment plus up to $500M milestone payments
- Notable quantitative metric: $152.5M paid in development/regulatory milestones for sepiapterin since acquisition, including $57.5M in 2025 alone
- Financial risk detail: Stressed need for substantial additional funding; reliance on equity, debt, collaborations, with potential dilution and restrictive covenants risks
Risk Factors
- Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026
- Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks
- Operational risk Emflaza U.S. orphan drug exclusivity expired Feb 2024 leading to increased generic competition impacting revenue
- Competitive risk Emflaza facing generic competition post orphan drug exclusivity expiration, negatively affecting net product revenue
- Financial risk Revenue concentration: Translarna net revenues $235.3M and Emflaza $146.4M in 2025, key products with regulatory uncertainties
Management Discussion & Analysis
- Revenue impact: upfront $1.0B from Novartis Agreement in Jan 2025, with potential $1.9B milestones, 40% US profits share, tiered double-digit royalties ex-US
- Operating cash flow $711.2M in 2025 vs $(107.7)M in 2024 and $(158.4)M in 2023, driven by Novartis upfront and clinical/commercial spend
- Investing cash flow used $862.0M in 2025, primarily for product rights acquisition, marketable securities, and fixed assets purchases
- Financing cash flow $331.1M in 2025 from Royalty Pharma fundings, option exercises, ESPP issuance, offset by contingent consideration and lease payments
- Forward risks: ongoing costs from commercialization, clinical trials, regulatory requirements; milestone and royalty payment obligations; dependence on market access and pricing; 2026 Convertible Notes interest $4.3M annually
AI summary of the PTCT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $357.8M, up from $210.2M YoY, driven by Sephience and Evrysdi royalties
- Sephience best performer: $181.9M sales vs $19.6M YoY; Emflaza worst, $25.1M vs $35.2M
- Net loss $0.1M implied by reported data, versus $0.1M net income YoY; no margin percentages disclosed
- Cash, equivalents and marketable securities $2.13B; operating cash flow $44.8M vs $745.5M
- $535.4M convertible-note proceeds, $328.8M used for 2026 note repurchases; headwinds from Emflaza generics and Translarna access risks
Risk Factors
- New regulatory risk: ST-920 acquisition adds FDA accelerated-approval uncertainty, with rolling BLA completion expected in fourth quarter 2026
- Most material update: Translarna U.S. development discontinued after NDA withdrawal in February 2026, while EEA authorization remains affected by the EC negative opinion
- Regulatory compliance risk: vatiquinone requires an additional controlled study after FDA’s August 2025 complete response letter
- Operational risk: three distributors each exceeded the undisclosed concentration threshold for net product sales in 2026
- Financial risk: $550.0 million 2031 Convertible Notes mature June 15, 2031, alongside $2,305.6 million royalty-sale liability carrying an 11.0% effective rate
AI summary of the PTCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Board-authorized share repurchase program announced November 3, 2026
- Potential shareholder return support and reduced share count, with program terms in Exhibit 99.1
Item 8.01: Other Events
- Board-authorized share repurchase program of up to $500.0 million
- Potentially supports per-share value and signals management confidence in the company’s valuation
Item EX-99.1: Item EX-99.1
- Board authorization for up to $500 million in common-stock repurchases, subject to market conditions
- Repurchases may include open-market purchases, trading plans, privately negotiated transactions and accelerated share repurchases
Item EX-99.1: Item EX-99.1
- Q3 revenue $357.6M, up from $201.7M, led by Sephience product revenue of $181.9M
- Full-year 2026 revenue guidance raised to $1.29B-$1.32B, product revenue to $960M-$990M
Item EX-99.2: Item EX-99.2
- 2026 product revenue guidance: $1.29-$1.32B, representing 64%-69% YoY growth
- Total revenue guidance: $960-$990M, with non-GAAP OpEx of $680-$720M
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Conference call scheduled for October 29, 2026 at 4:30 p.m. Eastern
- Management to review quarter ended September 30, 2026 financial results
Item 8.01: Other Events
- Acquisition completed September 21, 2026, expanding PTC Therapeutics’ development portfolio
- Rolling U.S. BLA submission for ST-920 expected in fourth quarter 2026
Item EX-99.1: Item EX-99.1
- Acquisition of ST-920 from Sangamo completed, adding a BLA-stage Fabry disease gene therapy to PTC’s rare-disease portfolio
- Rolling FDA BLA submission targeting completion in Q4 2026, with accelerated approval potential
Item 7.01: Regulation FD Disclosure
- PTC completed acquisition of ST-920 from Sangamo Therapeutics
- ST-920 is a BLA-stage, one-time AAV gene therapy candidate for Fabry disease
AI summaries of PTCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PTCT
Don't miss the next PTCT filing
- Alerts as it files. A push when PTCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PTCT, by share count.
- Ask anything. An AI agent that reads every PTCT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Boulding Mark Elliott | Sell | Nov 16, 2026 | 209 | $62.90 |
| Boulding Mark Elliott | M | Nov 16, 2026 | 2,812 | $25.69 |
| Boulding Mark Elliott | Sell | Nov 16, 2026 | 1,288 | $62.22 |
| Boulding Mark Elliott | M | Nov 16, 2026 | 2,812 | - |
| Boulding Mark Elliott | Sell | Nov 16, 2026 | 1,315 | $61.39 |
| SCHMERTZLER MICHAEL | Sell | Oct 14, 2026 | 2,118 | $59.52 |
| SCHMERTZLER MICHAEL | Sell | Oct 14, 2026 | 382 | $60.14 |
| Boulding Mark Elliott | M | Oct 9, 2026 | 192 | $39.42 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $806.8M | $1.7B |
| Operating Income | - | -$302.6M | $866.9M |
| Net Income | -$626.6M | -$363.3M | $682.6M |
| Op. Margin | - | -37.5% | 50.1% |
| Net Margin | - | -45.0% | 39.4% |
| Balance Sheet | |||
| Total Assets | $1.9B | $1.7B | $2.9B |
| Equity | - | -$1.1B | -$205.3M |
| ROE | - | 33.1% | -332.5% |
| Per Share | |||
| EPS | $-8.37 | $-4.73 | $7.78 |
| Cash Flow | |||
| Operating CF | - | -$107.7M | $711.2M |
| CapEx | $28.4M | $6.5M | $8.9M |
Source: XBRL data in PTC THERAPEUTICS, INC. (PTCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PTCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $2.64B |
| Q2 2026 | 34 | $3.45B |
| Q1 2026 | 34 | $2.70B |
| Q4 2025 | 31 | $2.96B |
| Q3 2025 | 31 | $2.10B |
| Q2 2025 | 29 | $1.69B |
| Q1 2025 | 26 | $1.18B |
| Q4 2024 | 23 | $889.6M |
- Goldman Sachs Group+1.01M (+163%)
- State Street Corp+913.6K (+20%)
- BlackRock+432.8K (+3%)
- Two Sigma Investments+116.0K (+1089%)
- AQR Capital Management+81.6K (+25%)
- D.E. Shaw & Co−930.2K (-60%)
- Invesco Ltd−517.2K (-55%)
- Morgan Stanley−342.3K (-31%)
- Citadel Advisors LLC−320.6K (-43%)
- T. Rowe Price Group−280.2K (-25%)
- Bridgewater Associates LP+145.4K
- Marex Group plc+3.5K
- FMR LLC (Fidelity)−1.40M
- Blackstone Group−8.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 242 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PTCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 9, 2026 | - | - | - |
| 4 | Oct 7, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 21, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Jul 30, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 10-Q | Jul 30, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
PTCT SEC filings: frequently asked questions
Are PTCT insiders buying or selling?
In the last 90 days, PTC THERAPEUTICS, INC. (PTCT) officers, directors and 10% owners reported no open-market purchases and 22 open-market sales worth $5.9 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PTCT stock?
As of September 30, 2026, the largest PTC THERAPEUTICS, INC. (PTCT) holders among the 13F filers tracked by SignalX were BlackRock ($932.7 million), State Street Corp ($357.1 million), Vanguard Portfolio Management LLC ($322.5 million), Vanguard Capital Management LLC ($234.4 million), Goldman Sachs Group ($105.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PTCT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PTC THERAPEUTICS, INC. (PTCT) reported revenue of $1.7 billion (up 114.5% from FY2024) and net income of $682.6 million. Diluted EPS was $7.78. The figures come from the XBRL data in the 10-K.
What are the main risks in PTCT's latest 10-K?
In the 10-K filed February 19, 2026, PTC THERAPEUTICS, INC. (PTCT) flagged: Regulatory risk U.S. FDA withdrawal of Translarna NDA resubmission for nmDMD after negative feedback in January 2026. Geopolitical exposure Sephience marketing approvals in U.S., EEA, Japan, Brazil with $111.2M 2025 net revenues, but country-specific pricing/licensing risks. (AI summary of the Risk Factors section.)
What did PTCT report in its latest 8-K?
PTC THERAPEUTICS, INC. (PTCT) filed an 8-K on November 3, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). Board-authorized share repurchase program announced November 3, 2026.
What are the latest PTCT SEC filings?
PTC THERAPEUTICS, INC. (PTCT) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 18, 2026.
What is PTCT's SEC CIK number?
PTC THERAPEUTICS, INC. (PTCT)'s SEC Central Index Key (CIK) is 1070081. EDGAR lists every PTCT filing under that number.
Ask anything about PTCT
The research agent reads PTCT's filings, financials, insider trades and 13F holders, then answers with sources.